Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)

Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton, Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, Mark Lunt, Roger Hesselstrand, Luc Mouthon, Alan Silman, Edith Brown, László Czirják, Jörg H W Distler, Oliver Distler, Kim Fligelstone, William J Gregory, Rachel Ochiel, Madelon Vonk, Codrina Ancuţa, Voon H Ong, Dominique Farge, Marie Hudson, Marco Matucci-Cerinic, Alexandra Balbir-Gurman, Øyvind Midtvedt, Alison C Jordan, Paresh Jobanputra, Wendy Stevens, Pia Moinzadeh, Frances C Hall, Christian Agard, Marina E Anderson, Elisabeth Diot, Rajan Madhok, Mohammed Akil, Maya H Buch, Lorinda Chung, Nemanja Damjanov, Harsha Gunawardena, Peter Lanyon, Yasmeen Ahmad, Kuntal Chakravarty, Søren Jacobsen, Alexander J MacGregor, Neil McHugh, Ulf Müller-Ladner, Gabriela Riemekasten, Michael Becker, Janet Roddy, Patricia E Carreira, Anne Laure Fauchais, Eric Hachulla, Jennifer Hamilton, Murat İnanç, John S McLaren, Jacob M van Laar, Sanjay Pathare, Susannah Proudman, Anna Rudin, Joanne Sahhar, Brigitte Coppere, Christine Serratrice, Tom Sheeran, Douglas J Veale, Claire Grange, Georges-Selim Trad, Christopher P Denton

Abstract

Objectives: The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult. We aimed to use an observational approach to compare effectiveness of currently used treatment approaches.

Methods: This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening). Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or 'no immunosuppressant'. Patients were assessed three-monthly for up to 24 months. The primary outcome was the change in modified Rodnan skin score (mRSS). Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights. As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival.

Results: Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant. 276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date). There were statistically significant reductions in mRSS at 12 months in all groups: -4.0 (-5.2 to -2.7) units for methotrexate, -4.1 (-5.3 to -2.9) for MMF, -3.3 (-4.9 to -1.7) for cyclophosphamide and -2.2 (-4.0 to -0.3) for no immunosuppressant (p value for between-group differences=0.346). There were no statistically significant differences in survival between protocols before (p=0.389) or after weighting (p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months.

Conclusions: These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed.

Trial registration number: NCT02339441.

Keywords: Cyclophosphamide; Methotrexate; Systemic Sclerosis; Treatment.

Conflict of interest statement

Competing interests: ALH has done consultancy work for Actelion, served on a Data Safety Monitoring Board for Apricus, received research funding and speaker's fees from Actelion, and speaker's fees from GSK. JHWD has consultancy relationships and/or has received research funding from Actelion, BMS, Celgene, Bayer Pharma, Boehringer Ingelheim, JB Therapeutics, Sanofi-Aventis, Novartis, UCB, GSK, Array Biopharma, Active Biotech, Galapagos, Inventiva, Medac, Pfizer, Anamar and RuiYi and is stock owner of 4D Science GmbH. OD has received consultancy fees from 4D Science, Actelion, Active Biotech, Bayer, Biogenidec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, Pfizer, Serodapharm, and Sinoxa and received research grants from Actelion, Bayer, Boehringer Ingelheim, Ergonex, Pfizer and Sanofi, and has a patent mir-29 for the treatment of systemic sclerosis licenced. WG has received teaching fees from Pfizer. FH has received research funding from Actelion. MEA has undertaken advisory board work and received honoraria from Actelion, and received speaker's fees from Bristol-Myers Squibb. LC has done advisory board work for Gilead and served Data Safety Monitoring Boards for Cytori and Reata. HG has done consultancy work and received honoraria from Actelion. UM-L is funded in part bu EUSTAR/EULAR. JMvL has received honoraria from Eli Lilly, Pfizer, Roche, MSD and BMS. AR receives funding from AstraZeneca. CPD has done consultancy for GSK, Actelion, Bayer, Inventiva and Merck-Serono, received research grant funding from GSK, Actelion, CSL Behring and Inventiva, received speaker's fees from Bayer and given trial advice to Merck-Serono.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Progression of patients through the study.
Figure 2
Figure 2
Modified Rodnan skin score (mRSS) during baseline and follow-up visits, by initial protocol. For each group of patients, according to their initial protocol, the distribution of the skin score is illustrated on the left-hand side by box and whisker plots (indicating the median and IQR) at baseline, 12 and 24 months. On the right-hand side, the distribution of individual 1-year changes in the skin score is described by histograms and a kernel density estimate. In addition, a vertical green line indicates the value of the average 1-year change in the skin score, irrespective of treatment choice. The bottom panel in the figure describes the estimated changes in mRSS (with 95% CI) according to initial protocol, based on the results from the adjusted model (described in table 3).
Figure 3
Figure 3
Kaplan-Meier estimated survival curves by treatment group.

References

    1. Nikpour M, Stevens WM, Herrick AL, et al. . Epidemiology of systemic sclerosis. Best Practice Res Clin Rheumatol 2010;24:857–69. 10.1016/j.berh.2010.10.007
    1. Rubio-Rivas M, Royo C, Simeon CP, et al. . Mortality and survival in systemic sclerosis : systematic review and meta-analysis. Sem Arthritis Rheum 2014;44:208–19. 10.1016/j.semarthrit.2014.05.010
    1. Nihtyanova SI, Schreiber BE, Ong VH, et al. . Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum 2014;66:1625–35. 10.1002/art.38390
    1. Merkel PA, Silliman NP, Clements PJ, et al. . Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2012;64:3420–9. 10.1002/art.34427
    1. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114–20. 10.1016/j.amjmed.2008.09.030
    1. Halpern SD, Karlawish JT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358–62. 10.1001/jama.288.3.358
    1. Pope JE, Bellamy N, Seibold JR, et al. . A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8. 10.1002/1529-0131(200106)44:6<1351::AID-ART227>;2-I
    1. Denton CP, Merkel PA, Furst DE, et al. . Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicentre, randomized, placebo-controlled Phase I/II trial of CAT-192. Arthritis Rheum 2007;56: 323–3. 10.1002/art.22289
    1. Kowal-Bielecka O, Landewé R, Avouac J, et al. . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis 2009;68:620–8. 10.1136/ard.2008.096677
    1. Rawlins MD. The Harveian Oration of 2008: On the evidence for decisions about the use of therapeutic interventions. London: Royal College of Physicians, 2008.
    1. Gagne J, Thompson L, O'Keefe K, et al. . Innovative research methods for studying treatments for rare diseases: methodological review. BMJ 2014;349:g6802 10.1136/bmj.g6802
    1. LeRoy EC, Black C, Fleischmajer R, et al. . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
    1. Clements P, Lachenbruch P, Siebold J, et al. . Inter- and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
    1. Clements PJ, Hurwitz EL, Wong WK, et al. . Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000;43:2445–54. 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>;2-Q
    1. Steen VD, Medsger TA. The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984–91. 10.1002/art.1780401110
    1. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79 10.1186/1477-7525-1-79
    1. Harel D, Thombs BD, Hudson M, et al. . Measuring fatigue in SSc: a comparison of the Short Form-36 Vitality subscale and Functional Assessment of Chronic Illness Therapy–Fatigue scale. Rheumatol 2012;51:2177–85. 10.1093/rheumatology/kes206
    1. Rannou F, Poiraudeau S, Berezne A, et al. . Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94–102. 10.1002/art.22468
    1. Brookhart MA, Schneeweiss S, Rothman KJ, et al. . Variable selection for propensity score models. Amer J Epidemiol 2006;163:1149–56. 10.1093/aje/kwj149
    1. Austin PC, Grootendorst P, Normand S-LT, et al. . Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study. Stat Med 2007;26:754–68. 10.1002/sim.2618
    1. Sato T, Matsuyama Y. Marginal structural models as a tool for standardization. Epidemiology 2003;14:680–6. 10.1097/01.EDE.0000081989.82616.7d
    1. Imbens G. The role of the propensity score in estimating dose-response functions. Biometrika 2000;87:706–10. 10.1093/biomet/87.3.706
    1. Fewell Z, Hernan MA, Wolfe F, et al. . Controlling for time-dependant confounding using marginal structural models. Stata J 2004;4:402–20.
    1. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Amer J Epidemiol 2008;168:656–64. 10.1093/aje/kwn164
    1. Tashkin DP, Elashoff R, Clements PJ, et al. . Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med 2006;354:2655–66. 10.1056/NEJMoa055120
    1. Tashkin DP, Roth MD, Clements PJ, et al. . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomsed controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708–19. 10.1016/S2213-2600(16)30152-7
    1. Van Laar JM, Farge D, Sont JK, et al. . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis. JAMA 2014;311:2490–8. 10.1001/jama.2014.6368
    1. Herrick A, Lunt M, Whidby N, et al. . Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010;37; 116–24.
    1. Khanna D, Denton CP, Jahreis A, et al. . Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised controlled trial. Lancet 2016;387:2630–40. 10.1016/S0140-6736(16)00232-4

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa